PriceTargets.com logo

GlycoMimetics - GLYC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $10.00
  • Forecasted Upside: 2,930.30%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.33 As of 11/20/2024 01:00 AM ET
▼ -0.05 (-13.16%)

This chart shows the closing price for GLYC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New GlycoMimetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GLYC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GLYC

Analyst Price Target is $10.00
▲ +2,930.30% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for GlycoMimetics in the last 3 months. The average price target is $10.00, with a high forecast of $12.00 and a low forecast of $8.00. The average price target represents a 2,930.30% upside from the last price of $0.33.

This chart shows the closing price for GLYC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 polled investment analysts is to hold stock in GlycoMimetics. This rating has held steady since April 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/26/2024TD CowenDowngradeBuy ➝ Hold
6/4/2024HC WainwrightReiterated RatingNeutral
5/6/2024Capital One FinancialDowngradeOverweight ➝ Equal Weight
5/6/2024HC WainwrightReiterated RatingBuy ➝ Neutral
3/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00
2/22/2024Capital One FinancialReiterated RatingOverweight
12/22/2023Capital One FinancialInitiated CoverageOverweight$12.00
8/3/2023HC WainwrightReiterated RatingBuy ➝ Buy$8.00
3/30/2023HC WainwrightReiterated RatingBuy$8.00
2/15/2023HC WainwrightLower TargetBuy$13.00 ➝ $8.00
8/4/2022HC WainwrightLower TargetBuy$14.00 ➝ $13.00
11/12/2021Jefferies Financial GroupUpgradeHold ➝ Buy$3.00 ➝ $4.00
11/2/2021HC WainwrightReiterated RatingBuy
5/3/2021Stifel NicolausBoost TargetBuy$8.00 ➝ $9.00
3/10/2021HC WainwrightReiterated RatingBuy
12/8/2020Roth CapitalBoost TargetPositive ➝ Buy$9.00 ➝ $15.00
7/31/2020HC WainwrightLower TargetBuy$16.00 ➝ $15.00
5/1/2020HC WainwrightReiterated RatingBuy$16.00
3/27/2020CowenInitiated CoverageBuy
3/2/2020HC WainwrightLower TargetBuy$18.00 ➝ $16.00
11/21/2019Roth CapitalLower Target$12.00 ➝ $9.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
5/24/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 4 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 0 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
GlycoMimetics logo
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $0.33
Low: $0.31
High: $0.37

50 Day Range

MA: $0.24
Low: $0.14
High: $0.49

52 Week Range

Now: $0.33
Low: $0.14
High: $3.53

Volume

3,463,417 shs

Average Volume

4,841,572 shs

Market Capitalization

$21.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.85

Frequently Asked Questions

What sell-side analysts currently cover shares of GlycoMimetics?

The following Wall Street sell-side analysts have issued research reports on GlycoMimetics in the last twelve months: Capital One Financial Co., HC Wainwright, StockNews.com, and TD Cowen.
View the latest analyst ratings for GLYC.

What is the current price target for GlycoMimetics?

0 Wall Street analysts have set twelve-month price targets for GlycoMimetics in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 2,930.3%. Capital One Financial Co. has the highest price target set, predicting GLYC will reach $12.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $8.00 for GlycoMimetics in the next year.
View the latest price targets for GLYC.

What is the current consensus analyst rating for GlycoMimetics?

GlycoMimetics currently has 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GLYC, but not buy more shares or sell existing shares.
View the latest ratings for GLYC.

What other companies compete with GlycoMimetics?

Other companies that are similar to GlycoMimetics include bluebird bio, Ikena Oncology, PMV Pharmaceuticals, Quince Therapeutics and CASI Pharmaceuticals. Learn More about companies similar to GlycoMimetics.

How do I contact GlycoMimetics' investor relations team?

GlycoMimetics' physical mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company's listed phone number is (240) 243-1201 and its investor relations email address is [email protected]. The official website for GlycoMimetics is www.glycomimetics.com. Learn More about contacing GlycoMimetics investor relations.